Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
about
CIViC databaseRecent developments and translational aspects in targeted therapy for metastatic breast cancerTwenty years of anti-HER2 therapy-associated cardiotoxicityClonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- VinorelbineRisk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.Precision medicine in breast cancer: reality or utopia?Therapeutic Considerations in Treating HER2-Positive Metastatic Breast CancerOutcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.HER2-positive breast cancer is lost in translation: time for patient-centered research.Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.Metastatic breast cancer: The Odyssey of personalization.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.Breast cancer treatment-induced cardiotoxicity.Targeting protein quality control pathways in breast cancer.A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer.Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.Progress in targeted therapy for breast cancerQ58714439
P2860
Q27612411-F982D747-9A66-44CC-A82A-AC3BDD6A7793Q28072755-46A05272-420B-4D61-975C-1DD0358292D0Q28079391-82E67B6A-DBC3-4B66-ADA0-1F4FA6627B2AQ28554790-C34DB512-0B3B-404C-89C9-372BE5C8FD90Q30248499-25B7C131-9931-4276-89A0-4D8C76ED7C3FQ33809114-8EA449FC-D0F1-45E1-84EA-678E04DF79B7Q34268618-1E86E897-0EE8-43E0-8E06-06F65F66D93CQ37580443-56719B03-2843-4401-AF48-3EA98D408C18Q38648765-0C8C3C4D-5818-4A6C-88E6-9279045CD981Q38861026-70EFB4E5-EDF9-485C-A804-245237E64E96Q38901163-1749CDDD-7DE8-45B8-9866-82E2AC8B5FA0Q38948950-047D02C1-0E98-4956-B9BA-0FDE3F49899EQ39428826-D44B0BC5-CA6A-43C8-9907-7629DB6C3610Q46087491-6BF4E269-785A-42B7-A81F-59CCD4A94B6AQ47556294-55B7EEEB-7010-4105-BDF5-1754294E9A57Q47594620-2F48624D-33B9-4B40-8068-BFFB79F7BDB7Q47598844-C7198CAC-2770-4DC3-A3D2-AD41675B3ABAQ50026716-C189EC7D-7AEE-4712-9EA9-A9D78E236501Q50057702-8D7D95D0-815C-4E6C-B1BC-67AC8A486189Q52578959-A887F267-5D96-4B88-A216-421874A420D7Q57109788-38E71859-49BD-460C-955E-ACD6339E9368Q58714439-BC80B5FE-3E5B-45BE-ABBF-867B7FAAB77A
P2860
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Afatinib plus vinorelbine vers ...... el, randomised, phase 3 trial.
@ast
Afatinib plus vinorelbine vers ...... el, randomised, phase 3 trial.
@en
Afatinib plus vinorelbine vers ...... el, randomised, phase 3 trial.
@nl
type
label
Afatinib plus vinorelbine vers ...... el, randomised, phase 3 trial.
@ast
Afatinib plus vinorelbine vers ...... el, randomised, phase 3 trial.
@en
Afatinib plus vinorelbine vers ...... el, randomised, phase 3 trial.
@nl
prefLabel
Afatinib plus vinorelbine vers ...... el, randomised, phase 3 trial.
@ast
Afatinib plus vinorelbine vers ...... el, randomised, phase 3 trial.
@en
Afatinib plus vinorelbine vers ...... el, randomised, phase 3 trial.
@nl
P2093
P50
P3181
P1433
P1476
Afatinib plus vinorelbine vers ...... el, randomised, phase 3 trial.
@en
P2093
Dah-Cherng Yeh
Jungsil Ro
Kunwei Shen
Kyung Hae Jung
Martina Uttenreuther-Fischer
Qingyuan Zhang
Rainer-Georg Goeldner
Sara Hurvitz
P304
P3181
P356
10.1016/S1470-2045(15)00540-9
P577
2016-03-01T00:00:00Z